ORYZON Raises €30 Million in Capital Increase

Core Insights - Oryzon Genomics successfully completed a €30 million capital increase by issuing 12,765,958 new shares at €2.35 per share, reflecting a 15.44% discount to the 5-day volume-weighted average price and a 19.38% discount to the closing price prior to the offering [1][5] - The offering was significantly oversubscribed, with strong demand from investors, including a €15 million order from a US-based institutional investor [1][5] - The funds raised will support the advancement of clinical programs, particularly for vafidemstat in CNS disorders and the oncology and hematology pipeline, while also strengthening the company's financial position [2][6] Company Overview - Oryzon Genomics, founded in 2000 in Barcelona, Spain, is a clinical-stage biopharmaceutical company specializing in epigenetics and personalized medicine, focusing on CNS disorders and oncology [3] - The company has a robust clinical portfolio, including two LSD1 inhibitors: vafidemstat (Phase III-ready) and iadademstat (Phase II) [3] - Oryzon's team consists of highly qualified professionals located in Barcelona, Boston, and San Diego, with a strong platform for biomarker identification and target validation [3] Clinical Development Focus - Vafidemstat is being developed for aggression-related CNS disorders, including Borderline Personality Disorder (BPD) and Autism Spectrum Disorder (ASD), and has shown positive results in clinical trials [8] - Iadademstat is a selective inhibitor of LSD1, currently in various clinical trials for hematologic cancers, demonstrating safety and preliminary signs of antileukemic activity [4][7] - The company is expanding its clinical development efforts for both vafidemstat and iadademstat through collaborations and additional studies [7][8] Use of Proceeds - The capital raised will be allocated to advance clinical development for vafidemstat and iadademstat, support CMC activities, and prepare for Phase IIb-III trials [6] - Funds will also be used to strengthen the company's balance sheet for future partnership or M&A negotiations and cover general administrative expenses [6]